Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HER2 inhibitor IAM1363

An orally bioavailable, immediate release (IR) capsule formulation containing a selective and irreversible inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor IAM1363 selectively targets, irreversibly binds to and inhibits the activity of wild-type (WT) and various HER2 mutants. This prevents HER2-mediated signaling and may lead to cell death in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization. IAM1363 is able to penetrate the blood-brain -barrier (BBB) and may be used in HER2-expressing brain tumors and brain metastases. IAM1363 does not inhibit epidermal growth factor receptor (EGFR) and avoids off-target EGFR-mediated toxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ENT-H1
IAM 1363
IAM-1363
IAM-H1
IAM1363
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search